New York, NY -- (ReleaseWire) -- 01/11/2013 --Geron Corporation (NASDAQ: GERN). California-based BioTime Inc. announced on January 7 that it will buy Geron Corporation’s human embryonic stem cell (hESC) assets, which includes intellectual property, 400 patents and patent applications, and the first ever US Food and Drug Administration-approved Phase I clinical trial of a hESC therapy.
Geron Corporation (Geron) is a biopharmaceutical company developing therapies for cancer. The Company has two product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials: metastatic breast cancer, advanced non-small cell lung cancer, essential thrombocythemia and multiple myeloma.
Find out more about GERN by getting the free full report: http://www.wallstreetreport.net/market-scan/?symbol=GERN
OCZ Technology Group Inc. (NASDAQ: OCZ) announced that it will demonstrate a pre-production version of its new flagship Vector SSD Series for PCI Express interfaces at the upcoming Consumer Electronics Show 2013, Venetian Hotel, Las Vegas, Nevada, from January 8th through 11th. OCZ Technology (Nasdaq: OCZ) filed to delay its 10-Q late Thursday. The Company requires additional time for compilation and review to insure adequate disclosure of certain information. The Company’s Audit Committee had also concluded that the Company should restate the results for the first quarter of fiscal 2013, as well as the results for certain quarters of fiscal 2012 and for the fiscal year 2012.
Find out more about OCZ by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=OCZ
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
WALL STREET REPORT